
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
Zealand will join efforts with Eli Lilly to design and develop therapeutic peptides for Type 2 diabetes and obesity.
Under the agreement, Zealand will collaborate with Eli Lilly in the design and development of peptide therapeutics for the treatment of Type 2 diabetes and obesity. The companies will share in the funding, risk, and reward of the program. Future expansion of the collaboration to additional drug targets and disease areas is possible. No financial terms of the agreement have been disclosed.
Source:






